Post by
faraj69 on May 10, 2016 1:03pm
Another one bites the dust
The company obviously doesn't know how to increase shareholder value. If they did, they should have reported earnings on Friday to build up investor interest and eventually share price. Also, it doesn't help when investors are looking to make big money, quick. When you break the numbers down, TST is obviously worth more than its current sp but trying to convince others of this is almost impossible. This news release is good news, believe it or not but not the news investors were looking for. I am looking forward for the SF convention and I will be visiting their head office in July.
As as for the situation we are in, I believe Ipsen is controlling the FDA's decision because as a shark of a company, why would they allow this product to get approved without profiting from it, on top of that, they would have to pay a $127 million reward for getting approved. Why do you think Ipsen put that stipulation? Because they knew it wouldn't get approved.
It it is my belief that TST needs to find a US partner to bid against Ipsen for this revolutionary product but at the end of the day Ipsen is the most appropriate partner.